Cut months and budget, not corners: An integrated E. coli pathway from gene to GMP

On 30 September 2026, enGenes Biotech and NorthX Biologics host a joint technical session on moving an E. coli-expressed protein from gene to GMP without losing time at the handovers. Delays often arise between expression development, process optimisation and manufacturing rather than in the science itself. Each transition adds complexity, cost and risk ahead of an IND- or IMPD-enabling batch.

The session looks at how a high-performing expression technology and an aligned end-to-end workflow can shorten that route. Ola Tuvesson, Chief Technology Officer at NorthX Biologics, and Jürgen Mairhofer of enGenes Biotech present. The webinar runs for roughly 40 minutes including live Q&A and starts at 15:00 CEST.

The content suits process development, CMC and manufacturing teams preparing a first clinical batch. Participation requires registration; sign up here.